Nanopath announces the close of a $25 million Series B financing to advance molecular testing for women's health, co-led by Norwest and SV Health Investors.
Amount Raised
$25 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareInvestors
Description
Nanopath, a point-of-care diagnostics company, has closed a $25 million Series B financing round to support the launch of its FDA 510(k) study for a new vaginitis test. The round was co-led by Norwest and SV Health Investors' MedTech Convergence Fund, with participation from other investors. This funding will also aid in the potential expansion of Nanopath's pipeline and the growth of its team in preparation for commercialization.
Quick answer
Nanopath raised $25 Million in a Series B round, dated November 10, 2026. Investors: Labcorp Venture Fund, Elderberry Ventures, Gingerbread Capital, Alumni Ventures, Norwest Venture Partners and SV Health Investors' Medtech Convergence Fund. Nanopath is based in Cambridge, Massachusetts, United States.
- How much did Nanopath raise?
- Nanopath raised $25 Million in a Series B round on November 10, 2026.
- Who invested in Nanopath?
- Labcorp Venture Fund, Elderberry Ventures, Gingerbread Capital, Alumni Ventures, Norwest Venture Partners and SV Health Investors' Medtech Convergence Fund are named as investors in this round.
- What does Nanopath do?
- Nanopath is a molecular diagnostics company disrupting traditional testing methodologies.
- Where is Nanopath based and how big is it?
- Nanopath is based in Cambridge, Massachusetts, United States. Fundz records about 25 employees.
- Who are the decision-makers at Nanopath?
- Fundz holds 2 contacts at Nanopath, including the Co-Founder & CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Nanopath that raised within 45 days of this round, from Fundz verified event records.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- Skribe Medical raised $1.6M (Pre-Seed) on November 12, 2026.
- BioWraptor raised $1.5M (Pre-Seed) on November 12, 2026.
- Neurosterix raised $105M (Series B) on November 11, 2026.
- Kardi Ai raised $5.9M (Series A) on November 11, 2026.
Who to call at Nanopath, and when
A new round usually means Nanopath is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nanopath raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nanopath, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nanopath. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nanopath raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansNanopath raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.